20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Collegium Pharmaceutical Inc (COLL) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Stoughton, United States with about 423 employees. Its market capitalization is roughly $773 million. In the fiscal year ended 2025-12-31, COLL reported $781M in revenue and $63M in net income.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
Interactive charts & full statements → Open the COLL valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $808M | $781M | $631M | $567M | $464M | $277M | $310M | $297M | $280M | $28M | $2M | $0M | $0M | — |
| Gross Profit | $485M | $463M | $377M | $326M | $209M | $151M | $180M | $103M | $115M | $26M | $1M | $0M | $0M | — |
| Gross Margin % | 60.0% | 59.4% | 59.8% | 57.6% | 45.1% | 54.4% | 58.0% | 34.7% | 40.9% | 90.9% | 87.5% | — | — | — |
| Operating Income (EBIT) | $159M | $187M | $170M | $167M | $33M | $18M | $56M | ($24M) | ($21M) | ($75M) | ($94M) | ($27M) | ($18M) | ($16M) |
| Operating Margin % | 19.6% | 24.0% | 26.9% | 29.5% | 7.2% | 6.4% | 18.1% | -8.0% | -7.4% | -265.0% | -5498.7% | — | — | — |
| Net Income | $48M | $63M | $69M | $48M | ($25M) | $72M | $27M | ($23M) | ($39M) | ($75M) | ($94M) | ($27M) | ($18M) | ($16M) |
| Net Margin % | 5.9% | 8.1% | 11.0% | 8.5% | -5.4% | 25.8% | 8.6% | -7.7% | -14.0% | -262.9% | -5504.1% | — | — | — |
| EBITDA | $587M | $401M | $342M | $308M | $173M | $87M | $118M | ($6M) | $92M | ($74M) | ($93M) | ($27M) | ($17M) | ($16M) |
| Earnings Per Share (EPS) | $1.12 | $1.58 | $1.71 | $1.15 | $-0.74 | $1.74 | $0.76 | $-0.68 | $-1.19 | $-2.47 | $-3.88 | $-2.01 | $-2.40 | $-2.17 |
| Shares Outstanding (M) | 32M | 40M | 40M | 42M | 34M | 41M | 35M | 33M | 33M | 30M | 24M | 14M | 7M | 7M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $200M | $194M | $205M | $209M | $188M | $178M | $182M | $159M |
| Gross Profit | $110M | $117M | $128M | $129M | $108M | $97M | $98M | $97M |
| Gross Margin % | 55.2% | 60.6% | 62.5% | 61.7% | 57.6% | 54.8% | 54.0% | 60.8% |
| Operating Income (EBIT) | $4M | $32M | $59M | $64M | $35M | $22M | $38M | $35M |
| Operating Margin % | 1.8% | 16.5% | 28.8% | 30.4% | 18.7% | 12.2% | 20.9% | 21.9% |
| Net Income | ($15M) | $14M | $17M | $32M | $12M | $2M | $13M | $9M |
| Net Margin % | -7.5% | 7.5% | 8.3% | 15.0% | 6.4% | 1.4% | 6.9% | 5.9% |
| EBITDA | $71M | $91M | $304M | $122M | $94M | $80M | $96M | $76M |
| Earnings Per Share (EPS) | $-0.46 | $0.36 | $0.43 | $0.80 | $0.31 | $0.07 | $0.31 | $0.23 |
| Shares Outstanding (M) | 32M | 40M | 40M | 39M | 39M | 33M | 40M | 40M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $330M | $329M | $205M | $275M | $124M | $104M | $94M | $28M | $169M | ($67M) | ($75M) | ($22M) | ($18M) | ($17M) |
| Capital Expenditures (CapEx) | $2M | $2M | $2M | $0M | $2M | $2M | $374M | $6M | $24M | $1M | $3M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | $328M | $328M | $203M | $274M | $123M | $102M | ($280M) | $21M | $145M | ($68M) | ($78M) | ($22M) | ($18M) | ($17M) |
| FCF Margin % | 40.6% | 42.0% | 32.2% | 48.4% | 26.4% | 36.7% | -90.3% | 7.2% | 51.7% | -238.8% | -4560.5% | — | — | — |
| Dividends Paid | — | — | — | $9M | — | $13M | $7M | — | — | $1M | $25M | $25M | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $71M | $57M | $123M | $78M | $72M | $55M | $85M | ($9M) |
| Capital Expenditures (CapEx) | $0M | $0M | $1M | $0M | $0M | $1M | $1M | $0M |
| Free Cash Flow (FCF) | $71M | $57M | $122M | $78M | $72M | $55M | $84M | ($9M) |
| FCF Margin % | 35.4% | 29.4% | 59.6% | 37.4% | 38.5% | 30.7% | 46.2% | -5.8% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.1B | $1.7B | $1.7B | $1.1B | $1.2B | $692M | $644M | $306M | $291M | $136M | $162M | $98M | $5M | $9M |
| Cash & Cash Equivalents | $129M | $251M | $71M | $239M | $174M | $186M | $174M | $170M | $147M | $119M | $153M | $96M | $2M | $8M |
| Total Liabilities | $1.8B | $1.4B | $1.4B | $948M | $979M | $489M | $458M | $219M | $200M | $31M | $27M | $13M | $17M | $3M |
| Total Debt (Short + Long-Term) | $1.1B | $811M | $854M | $668M | $702M | $251M | $258M | $12M | $12M | $1M | $4M | $7M | $13M | $1M |
| Total Shareholders' Equity | $312M | $302M | $229M | $195M | $195M | $203M | $186M | $87M | $92M | $104M | $135M | $85M | ($12M) | $6M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive COLL viewer.
About TickerBase · Data methodology & sources · Privacy · Terms